These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 18021301

  • 1. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 2. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

  • 3. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 4. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
    Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH.
    Ann Hematol; 2005 Oct 01; 84(10):675-80. PubMed ID: 16007424
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB, Valls Serón M, Geldhoff M, Havik SR, van der Ende A, Baas F, van der Poll T, Meijers JC, P Morgan B, Brouwer MC, van de Beek D.
    J Thromb Haemost; 2015 Nov 01; 13(11):2076-86. PubMed ID: 26340319
    [Abstract] [Full Text] [Related]

  • 6. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 01; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 7. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
    de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW.
    J Thromb Haemost; 2009 Jun 01; 7(6):919-27. PubMed ID: 19323787
    [Abstract] [Full Text] [Related]

  • 8. Evolution of thrombin formation and fibrinolysis markers, including thrombin-activatable fibrinolysis inhibitor, during severe meningococcemia.
    Fouassier M, Moreau D, Thiollière F, Frère C, Marquès-Verdier A, Souweine B.
    Pathophysiol Haemost Thromb; 2005 Jun 01; 34(6):284-7. PubMed ID: 16772741
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An evaluation of circulating activated TAFI in septic DIC: a case series and review of the literature.
    Totoki T, Ito T, Kakuuchi M, Yashima N, Maruyama I, Kakihana Y.
    Thromb J; 2022 Feb 07; 20(1):6. PubMed ID: 35130927
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 16. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 01; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 17. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.
    Stanne TM, Olsson M, Lorentzen E, Pedersen A, Gummesson A, Gils A, Jood K, Engström G, Melander O, Declerck PJ, Jern C.
    Thromb Haemost; 2018 Feb 01; 118(2):298-308. PubMed ID: 29378355
    [Abstract] [Full Text] [Related]

  • 18. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
    Zhou X, Declerck PJ.
    J Thromb Haemost; 2015 Jun 01; 13(6):1084-9. PubMed ID: 25773535
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.